辉瑞又双叒叕放弃一款口服 GLP-1,肥胖管线仅剩 1 款药物

Insight数据库
15 Apr

当地时间 4 月 14 日,辉瑞宣布终止开发口服胰高血糖素样肽-1(GLP-1)受体激动剂 Danuglipron(PF-06882961)。截图来源:企业官网在接受每日一次Danuglipron 治疗的 1400 多名患者中,肝酶升高的总体频率与同类已获批准的药物一致,但在其中一项剂量优化研究中,一名无症状参与者出现了潜在的药物性肝损伤,停用Danuglipron 后病情得到缓解。在审查了所有...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10